Sandra Bhatt

Sandra Bhatt leads the epigenetics research program at MD Anderson with expertise in HDAC inhibitors and their mechanisms of action in hematologic and solid tumors. Her research has elucidated how HDAC inhibitors induce cancer cell differentiation, apoptosis, and immune recognition. She contributed to the development and clinical evaluation of HDAC inhibitors including vorinostat and romidepsin in lymphoma and other hematologic malignancies. Her work has advanced understanding of the chromatin regulatory landscape in cancer cells.